Heterologous Prime/Boost Regimens Evaluated in Preventative HIV Vaccination

Official data suggests that nearly 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year.

Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development has been challenging but recent clinical trials have been promising. A new study in the Journal of Clinical Investigation discusses the results from a clinical trial that evaluated the immune response following different HIV vaccine regimes.

Screening for HIV/AIDS Infection
Efficient screening and better drugs help reduce the prevalence of HIV infection. A number of tests like ELIZA & Western Blot are used for screening HIV.

Nicole Frahm and colleagues tested prime-boost regimes combining a New York vaccinia HIV clade B (NYVAC-B) vaccine and a recombinant adenovirus 5–vectored (rAd5-vectored) vaccine in a cohort of healthy volunteers. Individuals that received the rAd5-vectored vaccine followed by the NYVAC-B vaccine exhibited the strongest anti-HIV immune responses. A regime in which individuals received the NYVAC-B vaccine prior to the rAd5-vectored vaccine was not as effective. The results from this study will be important for the design of further clinical trials to evaluate potential HIV-1 vaccine regimes.

Source-Eurekalert

Diabetes and HIV/AIDS Management
HIV/AIDS patients often present with diabetes or other metabolic disorders. The type of diabetes associated with HIV is Type-2 Diabetes Mellitus (T2DM).

About AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV

AIDS/HIV - Clinical Features Treatment FAQ Prevention & Transmission
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure, no vaccine, and it is not under control." - National Commission on AIDS, 1993.